Brain Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged between 18 and 88 years who have been diagnosed with glioblastoma (a type of brain tumour), confirmed by laboratory testing of tumour tissue, and whose cancer has come back for the first time after standard treatment involving surgery, chemotherapy with temozolomide, and radiotherapy.
• People whose blood test results meet specific thresholds for white blood cells, platelets, liver function, kidney function, and protein in urine (confirm exact values with trial site).
• People who have health insurance coverage.
• People who are able to give signed consent themselves, or, if unable to do so, whose nominated trusted person has provided consent on their behalf.

Who may not be able to join:

• People who have had bleeding in the brain or tumour that is causing symptoms.
• People with a Karnofsky performance score below 50% — a measure used by doctors to assess how well a person is able to carry out daily activities (confirm with trial site).
• People who have previously been treated with a type of drug called an anti-angiogenic (a drug that targets blood vessel growth in tumours), or with a chemotherapy wafer called Gliadel, at any stage of their illness.
• People with blood clotting disorders, particularly relevant to injectable treatments.
• People with known reasons they cannot have an MRI scan, such as a pacemaker, metal fragments in the eye, or implanted electrodes.
• People with a serious ongoing illness that is not well controlled, including another active cancer (except certain skin cancers that have been surgically removed, or cervical or breast cancer treated in its early, non-spreading stage).
• People with an active infection that is not under control.
• People with high blood pressure that remains above a certain level despite receiving treatment to control it.
• People with unstable heart or artery disease, or a growing aneurysm (a bulge in a blood vessel wall).
• People who have had a heart attack within the past 6 months.
• People who have had a stroke or peripheral artery-related event within the past 6 months.
• People with heart failure rated above a certain level of severity (confirm classification with trial site).
• People with a bleeding disorder such as haemophilia or von Willebrand disease.
• People with a kidney condition causing high levels of protein in the urine (above 2 g per 24 hours).
• People who have coughed up blood within the past month.
• People who have had a pulmonary embolism (a blood clot in the lungs) within the past month.
• People who have had surgery (other than brain surgery or biopsy) within the past month, or who have a planned necessary surgery coming up.
• People who have had a digestive fistula or bowel perforation that resolved less than 6 months ago.
• People with a known allergy or sensitivity to bevacizumab or any of its ingredients, including components derived from Chinese hamster ovary cells or other similar biological antibodies.
• People with severely reduced bone marrow function affecting blood cell production.
• People who are pregnant or breastfeeding. The trial requires that effective contraception is in place during treatment where needed.
• People who are under legal guardianship or have restricted legal freedom.
• People who are currently participating in another clinical trial that has an exclusion period still in effect.
• People who do not wish to take part in the study.

Important: Always verify eligibility with the trial site directly before applying.